<DOC>
	<DOCNO>NCT01442194</DOCNO>
	<brief_summary>The purpose world-wide prospective parallel-cohort study patient relapse form MS , either newly treat fingolimod receive another disease-modifying therapy , explore incidence select safety- related outcome monitor overall safety profile fingolimod condition routine medical practice .</brief_summary>
	<brief_title>Safety Study Patients With Multiple Sclerosis Treated Fingolimod Other Approved Disease-modifying Therapies</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients part routine clinical care accord locally approve label , either ; Starting fingolimod time study entry . Starting another approve DMT start within maximum 6 month prior study entry . Patients , able legal representative patient , willing provide write informed consent . Fingolimod patient constitute fingolimod cohort patient DMT constitute parallel cohort Patients previously currently treat cytotoxic agent ( e.g . mitoxantrone , cladribine , alemtuzumab ) natalizumab Patients participate simultaneously another study inclusion/exclusion criterion restrictive label interventional study unless study fingolimod last 1 month maximum Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>fingolimod</keyword>
	<keyword>observational study</keyword>
</DOC>